featured
Oral Decitabine–Cedazuridine vs Intravenous Decitabine for Myelodysplastic Syndromes and Chronic Myelomonocytic Leukaemia
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Haematology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study
Lancet Haematol 2024 Jan 01;11(1)e15-e26, G Garcia-Manero, J McCloskey, EA Griffiths, KWL Yee, AM Zeidan, A Al-Kali, HJ Deeg, PA Patel, M Sabloff, MM Keating, N Zhu, NY Gabrail, S Fazal, J Maly, O Odenike, H Kantarjian, AE DeZern, CL O'Connell, GJ Roboz, L Busque, R Buckstein, H Amin, J Randhawa, B Leber, A Shastri, KH Dao, A Oganesian, Y Hao, HN Keer, M Azab, MR SavonaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.